Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
171 hedge funds and large institutions have $877M invested in Ariad Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 30 closing their positions.
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
17% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 48
10% more capital invested
Capital invested by funds: $801M → $877M (+$76.3M)
3% more funds holding
Funds holding: 166 → 171 (+5)
7% more call options, than puts
Call options by funds: $53.1M | Put options by funds: $49.5M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$51.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$24.7M |
| 3 |
Renaissance Technologies
New York
|
+$17.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.73M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$17.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$16.7M |
| 4 |
Barclays
London,
United Kingdom
|
-$14M |
| 5 |
PC
PointState Capital
New York
|
-$12.5M |
ARIA Hedge Fund Activity: Q1 2014 in Review
171 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q1 2014, worth a combined $877M — up 9.5% from $801M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ARIA positions and 30 closed out — a net gain of 6 holders — while 56 added to existing stakes and 48 trimmed.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $51.6M. The largest seller was Fidelity Investments, cutting an estimated $28.7M.
- 171 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q1 2014, up from 166 in Q4 2013.
- Funds reported $877M of Ariad Pharmaceuticals Inc stock for Q1 2014, up 9.5% quarter-over-quarter.
- 36 funds opened new Ariad Pharmaceuticals Inc positions in Q1 2014 and 30 closed out, a net change of +6 holders.
- The largest Ariad Pharmaceuticals Inc buyer in Q1 2014 was Slate Path Capital, an estimated $51.6M added.
- The largest Ariad Pharmaceuticals Inc seller in Q1 2014 was Fidelity Investments, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2014.